StockMirror — Stock Screener

TORNTPHARM Q3 FY26 Results & Earnings Analysis

Sentiment: Good (Confidence: high)

Earnings Summary

Torrent Pharma reported strong Q3 FY26 results with 18% revenue growth and 19% EBITDA growth, led by India (14%) and Brazil (27%). The acquisition of JB Pharma is progressing, with consolidation started and INR 400-450 cr cost synergies identified. Near-term headwinds include a supplier disruption in Germany (revenue down 6% CC) and cautious outlook on pricing for the upcoming GLP-1 launch in Brazil. Management remains confident in long-term growth through geographic expansion and pipeline execution.

Management Tone

Revenue Growth Drivers

Growth vs Margin Focus

Management is driving growth through geographic expansion, pipeline launches, and acquisition (JB). Simultaneously, they are focused on margins through identified cost synergies from the acquisition and plans to discontinue low-margin trade generics business of JB.

About Torrent Pharmaceuticals Limited

Torrent Pharmaceuticals Limited (TORNTPHARM) is listed on NSE. View the latest earnings analysis, AI-powered insights, and sentiment data on StockMirror.

Explore More